Related Experiment Video
Updated: May 29, 2026
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
Pediatric ependymomas: will molecular biology change patient management?
Jacques Grill1, Guillaume Bergthold, Céline Ferreira
1Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Institute, Villejuif, France. grill@igr.fr
Purpose Of Review:
Ependymomas remain a therapeutic challenge in pediatric neuro-oncology. These tumors are chemoresistant and rather radioresistant and until recently little was known about their biology.
Recent Findings:
Histopathological grading of ependymomas according to the WHO classification is neither reproducible, nor correlated with outcome, especially in young children. Characterization of molecular abnormalities in ependymomas offers now a better understanding of their initiation and progression; different biological subtypes of tumors have been described and would need further validation. The identification of new prognostic biomarkers, such as tenascin-C overexpression or chromosome 1q gain, will considerably help patient stratification in future trials. Finally, the recent discovery of specific pathways involved in ependymomas oncogenesis, such as Notch-1or EPHB2 offers new perspectives for the development of targeted therapies.
Summary:
A comprehensive biological work-out including CGHarray and immunohistochemistry for specific biomarkers should now be recommended for the current management of pediatric ependymoma, especially in young children if radiotherapy has to be omitted in the first line of treatment.
Insights
Pediatric ependymomas are challenging tumors. Molecular characterization reveals subtypes and biomarkers, guiding targeted therapies and improving patient stratification for better treatment outcomes.
Area of Science:
- Pediatric neuro-oncology
- Cancer biology
- Molecular diagnostics
Background:
- Ependymomas are difficult to treat in children due to chemoresistance and radioresistance.
- Limited understanding of ependymoma biology has historically hindered therapeutic advancements.
Purpose of the Study:
- To review current understanding of pediatric ependymoma biology.
- To explore novel diagnostic and therapeutic strategies.
- To improve patient stratification and outcomes.
Main Methods:
- Review of histopathological and molecular data.
- Analysis of WHO classification limitations.
- Identification of prognostic biomarkers and oncogenic pathways.
Main Results:
- WHO histopathological grading lacks reproducibility and outcome correlation in young children.
- Molecular characterization has identified distinct ependymoma subtypes and potential prognostic biomarkers (e.g., tenascin-C, chromosome 1q gain).
- Discovery of key oncogenic pathways (e.g., Notch-1, EPHB2) offers targets for novel therapies.
Conclusions:
- Comprehensive molecular profiling (CGH array, immunohistochemistry) is recommended for pediatric ependymoma management.
- This approach aids in patient stratification, particularly for young children where radiotherapy may be omitted initially.
- Advances in understanding ependymoma biology pave the way for targeted therapeutic development.
